Survodutide Research Overview (also known as BI 456906, GLP-1/glucagon dual agonist, Survodutide peptide)
A dual GIP/GLP-1 receptor agonist studied for its complementary approach to glucose regulation and adiposity reduction. Research interest includes weight-loss outcomes, insulin sensitivity improvement, and appetite control.
What Is Survodutide?
Survodutide (BI 456906) is a once-weekly injectable dual agonist of GLP-1 and glucagon receptors developed by Boehringer Ingelheim and Zealand Pharma. Sharing the dual GLP-1/glucagon mechanism with Mazdutide, survodutide is being evaluated primarily for obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH) — leveraging glucagon receptor agonism's unique capacity to directly reduce hepatic fat accumulation.
Dual Mechanism: GLP-1 + Glucagon
GLP-1 receptor agonism provides appetite suppression, glucose-dependent insulin stimulation, and reduced gastric emptying. Glucagon receptor agonism adds thermogenic energy expenditure, hepatic fatty acid oxidation (directly reducing liver fat), and lipolysis from adipose tissue. The GLP-1 component prevents the hyperglycemia that pure glucagon agonism would cause — the fundamental design logic of dual GLP-1/glucagon compounds.
Clinical Data
Phase 2 trials in obesity reported approximately 15% body weight reductions at 46 weeks at the highest dose tested. In MASH-specific trials, liver fat reduction was particularly pronounced compared to semaglutide — supporting the hypothesis that glucagon receptor co-agonism adds meaningful hepatic benefit beyond what GLP-1 alone achieves. Phase 3 trials in MASH and obesity are ongoing.
Quick Reference
| Literature-Reported Dose Range | 0.6mg starting, titrate by 0.6mg every 4 weeks to 3.6-6.0mg |
| Literature-Reported Frequency | Once weekly on the same day each week |
| Literature-Reported Cycle Length | Long-term therapy - trials up to 76 weeks, likely continuous use |
| Literature-Reported Washout | No cycling required - continuous weekly therapy |
| Storage | Refrigerate at 2-8°C, protect from light, use within 4 weeks of reconstitution |
| Sites Reported in Studies | Subcutaneous: abdomen (2+ inches from navel), upper thigh, or upper arm |
| Timing | Any time of day, with or without food - maintain consistent weekly schedule |
Research Indications
Weight Loss
Obesity Without Diabetes
Phase 2 trial showed 14.9% mean weight loss at 46 weeks with 4.8mg dose, 55% achieving ≥15% weight loss
Obesity With Type 2 Diabetes
Superior weight loss vs semaglutide (-8.7% vs -5.3%) at 16 weeks in head-to-head trial
Sustained Weight Management
Dual mechanism addresses both energy intake and expenditure, potentially reducing weight regain
Metabolic
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 2 trial: 62% achieved MASH improvement without fibrosis worsening at 4.8mg dose
Liver Fat Reduction
63-67% achieved ≥30% liver fat reduction in MASH trial, maintained in cirrhosis patients
Type 2 Diabetes Control
Dose-dependent HbA1c reduction up to -1.6% in Phase 2 trial on metformin background
Cardiovascular
Blood Pressure Reduction
Secondary endpoint in Phase 3 trials based on expected cardiovascular benefits from weight loss
Cardiovascular Risk Factors
SYNCHRONIZE-CVOT trial evaluating MACE outcomes in 4,935 high-risk participants
Metabolic Syndrome Components
Improvements in multiple parameters including waist circumference and glycemic control
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Obesity - Standard Protocol | 3.6-6.0mg | Once weekly | SubQ (abdomen/thigh) |
| Obesity - Conservative Start | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | SubQ |
| MASH Treatment | 2.4-4.8mg | Once weekly | SubQ |
| Type 2 Diabetes | 0.3-2.7mg | Once weekly | SubQ |
Timing
Any time of day, with or without food - maintain consistent weekly schedule. Typical onset: weight loss begins week 4-8, peak effects after reaching target dose (week 24+).
Peptide Interactions
Both are GLP-1 receptor agonists - combining may lead to excessive GLP-1 activation and increased gastrointestinal side effects. Not recommended without medical supervision.
No direct interaction. Can be used together as demonstrated in Phase 2 trials with type 2 diabetes patients on metformin background therapy.
No known interactions. Phase 3 trials allow concurrent use of SGLT2 inhibitors with appropriate monitoring of glycemic control.
Risk of hypoglycemia when combined. Monitor blood glucose closely and consider sulfonylurea dose reduction if needed.
May require insulin dose adjustment due to improved glycemic control. Start with lower insulin doses and titrate based on glucose monitoring.
Delayed gastric emptying may affect absorption. Take oral contraceptives at least 1 hour before survodutide injection.
May affect warfarin absorption due to delayed gastric emptying. Monitor INR more frequently when initiating or changing survodutide dose.
Risk of excessive glucagon receptor activation. Do not combine with other glucagon receptor agonists.
Reported Research Timeline
01Week 1–4 (reported in cited studies): possible nausea, reduced appetite - most common during dose escalation
02Week 4–8 (reported in cited studies): initial weight loss begins, improved satiety between meals
03Week 8–16 (reported in cited studies): progressive weight loss, potential improvement in energy levels
04Week 16–24 (reported in cited studies): approaching steady-state levels, more consistent effects
05Week 24+ (reported in cited studies): sustained weight loss, metabolic improvements become more apparent
06Long-term (reported in cited studies): average 15-19% weight loss at higher doses by week 46
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Common GI side effects: nausea (40-66%), diarrhea (25-49%), vomiting (15-41%)
Most GI effects occur during dose escalation - use flexible dosing if needed
Heart rate may increase slightly (mean 2-5 bpm) - monitor if cardiac conditions
Not recommended in pregnancy or breastfeeding - use contraception
No dose adjustment needed for hepatic impairment including cirrhosis
Monitor blood glucose if on diabetes medications - may need adjustment
Seek Medical Attention If:
Severe persistent nausea/vomiting preventing oral intake
Signs of pancreatitis: severe abdominal pain radiating to back
Allergic reactions: rash, itching, difficulty breathing
Severe hypoglycemia if combined with insulin/sulfonylureas
Gallbladder symptoms: right upper quadrant pain, especially after fatty meals
Significant tachycardia or arrhythmias
Quality Indicators
Verified Marker
Clear to slightly opalescent solution
Properly reconstituted survodutide should be clear or have slight opalescence without visible particles
Verified Marker
Sealed vial with intact rubber stopper
Ensures sterility and proper storage conditions have been maintained
Verified Marker
Within expiration date
Check both powder and bacteriostatic water expiration dates before use
Acceptable Range
Slight foam after reconstitution
Normal if disappears within minutes - allow to settle before drawing dose
Quality Concern
Cloudy solution or visible particles
Do not use - may indicate contamination or degradation
Quality Concern
Discoloration of powder or solution
Should be white to off-white powder and colorless solution when reconstituted
Research Citations
- Phase 2 Obesity Trial Without Diabetes (2024)
Human | 0.6-4.8mg weekly | 46 weeks | Up to 14.9% weight loss - Phase 2 MASH and Fibrosis Trial (2024)
Human | 2.4-6.0mg weekly | 48 weeks | 47-62% MASH improvement - Phase 2 Type 2 Diabetes Trial (2023)
Human | 0.3-2.7mg weekly | 16 weeks | Superior to semaglutide - Preclinical Pharmacology Study (2022)
Animal/In vitro | Various doses | EC50 0.52nM GCGR, 0.33nM GLP-1R - A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal AJ, Bedossa P, Fraessdorf M, 2024, N Engl J Med - Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker DJ, 2024, Diabetes Care - Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis M, Chakhtoura M, Rhayem C, 2025, Pharmacol Rev - Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis
Lawitz EJ, Fraessdorf M, Neff GW, 2024, J Hepatol - Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, 2024, Lancet Diabetes Endocrinol
Research Focus
Weight loss, GLP-1/glucagon dual agonism, NASH/MASH, Liver fat reduction, Metabolic health
Verified Vendors Carrying Survodutide
Frequently Asked Questions
What should researchers watch for with Survodutide?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Survodutide?
Week 1–4 (reported in cited studies): possible nausea, reduced appetite - most common during dose escalation
How is Survodutide typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →